Momenta Pharmaceuticals (MNTA) : 4 brokerage houses believe that Momenta Pharmaceuticals (MNTA) is a Strong Buy at current levels. 2 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Momenta Pharmaceuticals (MNTA). Zacks Investment Research suggests a Hold with a rank of 3. 1 others believe that the stock has run up ahead of its fundamentals and advise a Strong Sell on the stock.The median of all the 7 Wall Street Analysts endorse the stock as a Buy with a rating of 2.14.
Momenta Pharmaceuticals (MNTA) : The consensus price target for Momenta Pharmaceuticals (MNTA) is $14.29 for the short term with a standard deviation of $4.61. The most optimist securities analyst among the 7 who monitor the stock believes that the stock can reach $20, however, the pessimist price target for the company is $6.
Also, Equity Analysts at the Maxim Group downgrades the rating on Momenta Pharmaceuticals (NASDAQ:MNTA). The brokerage firm has issued a Sell rating on the shares. The shares were previously rated Hold. The rating by the firm was issued on September 7, 2016.
Momenta Pharmaceuticals (NASDAQ:MNTA): The stock opened in the green at $11.69 on Thursday, but the bulls found it difficult to push the prices higher. The stock reached a high of $11.74 and a low of $11.48 for the day. The stock did not find buyers even at the lows and closed at $11.66 recording a loss of -0.26%. 469,032 shares exchanged hands during the trading day. The stock had closed at $11.69 in the previous days trading.
Momenta Pharmaceuticals, Inc. (Momenta) is a biotechnology company focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has three product areas: Complex Generics, Biosimilars and Novel Therapeutics. The Companys product, a generic version of Lovenox (enoxaparin sodium injection), was approved by the United States Food and Drug Administration. The Company is developing Complex Generics, such as Enoxaparin Sodium Injection and M356. The Company is developing Bosimilars, including M923 and M834. The Company is developing Novel Therapeutics, including Necuparanib. The Company is developing M356 as a generic version of Copaxone. The Company is developing M923, a biosimilar of HUMIRA. The Company is developing M834 as a biosimilar of ORENCIA.